Uncover hidden gems in the stock market with the 'Undercovered Dozen' series featuring undervalued stocks with potential for ...
Royalty Pharma's Q3 results show growth driven by strong portfolio performance and acquisitions. See why we recommend a buy ...
Q3 2024 Earnings Call Transcript November 6, 2024 UroGen Pharma Ltd. beats earnings expectations. Reported EPS is $-0.55, ...
H.C. Wainwright analyst Joseph Pantginis has maintained their bullish stance on LXRX stock, giving a Buy rating on October 31. Joseph ...
Third quarter global net product sales of $90.3 million; 2024 guidance increased to $330 - 335 million Volixibat granted ...
Analyst Mayank Mamtani from B.Riley Financial maintained a Buy rating on Centessa Pharmaceuticals (CNTA – Research Report ... the company to concentrate resources on its OX2R agonist franchise. This ...
Centessa had recently conducted an interim analysis of a phase 2 study of its drug, called SerpinPC, which is designed to ...
Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 mil ...
Fierce Pharma Asia—AstraZeneca's China fallout; Pfizer's $1B plan in China; Incyte-Sun JAK dispute
Sun Pharma's JAK inhibitor Leqselvi was slapped ... with execs warning of more obstacles ahead The Gardasil HPV vaccine franchise continued its decline for Merck & Co. because of lower demand ...
A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...
The Motley Fool on MSN12d
Is Pfizer Stock a Bargain for Long-Term Investors?Pfizer's non-COVID product revenues surged 14% operationally last quarter. The oncology business delivered exceptional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback